Potential Role of Acupuncture Treatment in Neuronal and Network Dysfunction in Patients With Vascular Cognitive Impairment

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04087499
Collaborator
(none)
80
1
2
34
2.4

Study Details

Study Description

Brief Summary

Vascular cognitive impairment (VCI) is a broad dimensional term, ranging from mild cognitive impairment without incapacity on activity of daily living to vascular dementia (VaD), referred to as significant cognitive impairment and decline in function status.

In this three-year project, we aim to evaluate the effects of biochemical data, early clinical variables, neuroimaging results, and intervention of acupuncture treatment on vascular event related cognitive impairment in crossectional analysis and longitudinal follow-up.

Condition or Disease Intervention/Treatment Phase
  • Device: Acupuncture
N/A

Detailed Description

Stroke is a common cerebrovascular disease of the central nervous system leading to serious medical complication. It results in a high mortality rate and increased disability rate. Stroke survivors may have long-lasting consequences, including motor dysfunction, sensibility dysfunction, and cognitive impairment]. Cognition is a key component of rehabilitation and recovery; therefore it is associated with poor engagement in rehabilitee and outcomes including increased mortality. As vascular dementia (VaD) is considered the second-most-common type of dementing illness, accounting for a significant proportion of total dementia case, vascular cognitive impairment (VCI) is a broader dimensional term, ranging from mild cognitive impairment without incapacity on activity of daily living to VaD, referred to as significant cognitive impairment and decline in function status.

Acupuncture is an ancient Chinese medical technique in which fine, stainless steel needles are inserted into certain anatomical locations of the body surface to elicit neurohormonal responses of the body system via nerve stimulation. Acupuncture are reported to be probably effective in improving cognitive function in vascular dementia animal models via multiple mechanisms such as anti-apoptosis, antioxidative stress reaction, and metabolism enhancing of glucose and oxygen.

Motor features may not parallel to the cognitive changes, it will serve as the disease progression marker. Unified Parkinson's Disease Rating Scale (UPDRS)-part III scores and NIH Stroke Scale (NIHSS) will be used.

  1. At Kaohsiung Chang Gung Memorial Hospital, all the patients (n=80) will be included and receive a Standardized Acupuncture intervention; 40 will be treated with regular medication; 40 will be treated with acupuncture and regular medication.

  2. For acupressure program, all participants are treated in supine position, and a certified TCM physician applied firm pressure (3 to 5 kg of pressure) with fingertips in a circular motion at a speed of 2 circles per second for a duration of one minute per acupoint. The complete process lasts for 8 minutes.

Cognitive function, Motor function, Mood and Sleep will be evaluated at baseline and follow-up period of time at 3 month, 6 month, and 12 month.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Potential Role of Acupuncture Treatment in Neuronal and Network Dysfunction in Patients With Vascular Cognitive Impairment
Actual Study Start Date :
Sep 1, 2019
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: regular medication treatment

regular medication treatment

Device: Acupuncture
acupuncture treatment on selected acupoint

Experimental: acupuncture and regular medication treatment

acupuncture and regular medication treatment

Device: Acupuncture
acupuncture treatment on selected acupoint

Outcome Measures

Primary Outcome Measures

  1. Change from baseline sleep quality at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Analogous variables were extracted from actigraphy. The sleep variables collected were sleep start time, sleep end time, sleep duration, sleep efficiency, and wake after sleep onset time, and the activity variables collected were heart rate activity score,activity amount, and activity intensity

Secondary Outcome Measures

  1. Change from baseline neuro-behavioral performances at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Cognitive Abilities Screening Instrument (CASI). In addition to general cognitive performance, CASI was used to evaluate specific domains, including short-term memory, attention and concentration, abstraction, visual construction, language, and list-generating fluency.

  2. Change from baseline motor function (UPDRS) at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Unified Parkinson's Disease Rating Scale (UPDRS)-part III scores for parkinsonian features.

  3. Change from baseline motor function (NIHSS) at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    NIH Stroke Scale (NIHSS) score 0-24.

  4. Change from baseline continuous motor function at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Physical activity was measured using accelerometers.

  5. Change from baseline memory performances at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Verbal memory were evaluated by using Chinese Version Verbal Learning Test (CVVLT).Visual-spatial abilities.

  6. Change from baseline executive performances at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Attention and executive function was evaluated by Trail Making Test B.

  7. Change from baseline executive performances (Stroop interference test) at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Attention and executive function was evaluated by Stroop interference test.

  8. Change from baseline executive performances (calculation) at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    As the calculation ability depends on executive function, calculation ability was evaluated to reflect part of executive function.

  9. Change from baseline abstract thinking at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Abstract reasoning was evaluated by using similarities (conceptualization) in frontal assessment battery-Similarities.

  10. Change from baseline language performances at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Boston Naming Test were used to evaluate language ability in naming.

  11. Change from baseline fluency performances at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    Semantic category fluency.

  12. Change from baseline neuropsychiatric symptoms at 3 months, 6 months, 12 months [3 months, 6 months, 12 months]

    The neuropsychiatric symptoms of the participants were measured using the Neuropsychiatric Inventory.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Fulfill the diagnostic criteria of vascular cognitive impairment
Exclusion Criteria:
  1. Systemic inflammatory disease with on-going treatment

  2. Severe psychiatric disease, such as major depressive disorder or schizophrenia

  3. Severe traumatic brain injury

  4. Unable to tolerate exam of brain MRI

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan 83301

Sponsors and Collaborators

  • Chang Gung Memorial Hospital

Investigators

  • Principal Investigator: YaTing Chang, MD,PhD, Chang Gung Memorial Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier:
NCT04087499
Other Study ID Numbers:
  • 201802103A3
First Posted:
Sep 12, 2019
Last Update Posted:
Oct 3, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2019